DIABETES (1 of 5) Generic. Generic $0 $5 $5-10 $0 $0 $0. Generic $0 $5 $5-10. Generic. Generic $0 $5 $5-10 $0 $0 $0. Generic $0 $5 $5-10 $0 $0 $0

Size: px
Start display at page:

Download "DIABETES (1 of 5) Generic. Generic $0 $5 $5-10 $0 $0 $0. Generic $0 $5 $5-10. Generic. Generic $0 $5 $5-10 $0 $0 $0. Generic $0 $5 $5-10 $0 $0 $0"

Transcription

1 Metformin DIABETES (1 of 5) Glucophage Glucophage XR ER $7 (500mg) $7 (500mg) $5 $5 500mg, 750mg only 500mg, 750mg only Sulfonylurea/Combinations Amaryl Glucotrol glimepiride glipizide $5 $5 Glucotrol XL glipizide ER $12 $5 Micronase, Diabeta glyburide $5 Metaglip Glucovance glipizide/metfor min glyburide/metf ormin $22 $5 $15 $5 TZD/Combinations Actos pioglitazone $10 $5 must fail Duetact pioglitazone/ glimepiride $122 $5 ACTOplus met pioglitazone/m etformin $55 $5 must fail

2 DIABETES (2 of 5) DPP-4 Inhibitors/Combinations Januvia sitagliptin $469 $25 $25 Tradjenta linagliptin $338 $25 $25 Kombiglyze XR saxagliptin/metf ormin ER $394 $50 GLP-1 Mimetic Byetta exenatide $474 (3ml) $50 Bydureon Bydureon BCise Onglyza saxagliptin $316 $50 Nesina alogliptin $172 $5 $5-$10 Kazano alogliptin/metfo $172 $5 $5-$10 rmin Janumet sitagliptin/metfo $435 $25 $25 rmin Janumet XR sitagliptin/metfo $435 $25 $25 rmin ER exenatide ER $514 (8ml) $50 $25 Victoza liraglutide $440 6ml $25 $25 Trulicity dulaglutide 99 $25 $25 Ozempic Semaglutide $773 Preferred $25 $25 ** : Trulicity, Victoza, Ozempic - trial of 30 days Januvia, Janumet, Janumet XR trial of, sulfonylurea, or insulin sensitizer. * ***: all GLP-1 memetic drugs need a, even Bydureon and Victoza which are the drugs. Non- drugs may require explaining why Bydureon and Victoza are a good choice. ***United Health : Nesina, Kazano, Trulicity, Tanzeum, --trial of Metformin 1500mg qd for 90 days

3 SGLT2 Inhibitors/Combinations DIABETES (3 of 5) Invokana canagliflozin $453 $25 Invokamet canagliflozin/met formin $453 $25 Invokamet XR canagliflozin/met formin $453 $25 Jardiance empagliflozin $415 $25 Synjardy empagliflozin/me tformin $415 $25 Synjardy XR empagliflozin/me tformin $415 $25 Farxiga dapagliflozin $457 $25 Xigduo XR dapagliflozin/met formin ER $457 $25 Steglatro ertugliflozin $287 $50 Segluromet ertugliflozin/metf ormin $274 $50 : - Jardiance - Only FDA approval use that is consistent with ADA or AACE guidelines for T2DM and A1C monitoring within the past 3 months. : Invokana, Invokamet, Invokamet XR - must try, sulfonylurea, or insulin sensitizer : Steglatro, Segluromet - must try, er, or Riomet wtihn past 100 days United Health : Steglatro, Segluromet --90 day trial of 1500mg/day

4 Insulin (Rapid-Acting) DIABETES (4 of 5) $210 10ml, Apidra glulisine $430 15ml $ ml, Humalog lispro $423 15ml Pen, Vial Admelog lispro $485 vial, Novolog aspart Insulin (Short-Acting) $197 10ml, $375 15ml vial, vial, vial, vial, vial, vial - ( - ) Humulin R insulin $89 vial OTC vial only vial, vial, vial Novolin R insulin $28 Walmart OTC vial $15 vial Insulin (Intermediate-Acting) Humulin N NPH $309 15ml OTC vial, Novolin N NPH $29 Walmart OTC vial, $15 vial Insulin (Long-Acting) Lantus glargine $240 10ml, $371 15ml vial, vial, Vial, Pen vial, vial, vial, Pen, Vial vial, vial Basaglar glargine $248 Pen $5 Toujeo glargine $308 bayer Levemir detemir $189 10ml Insulin (Ultra Long-Acting) $25 Tresiba degludec??? $5

5 Insulin (Pre-Mixed) DIABETES (5 of 5) Humalog Mix 50/50 lispro mix $131 10ml, $841 15ml $5 vial, vial, vial Humalog Mix 75/25 Humulin 70/30 lispro mix NPH/reg mix $158 10ml, $423 15ml $90 10ml, $385 15ml Novolin 70/30 NPH/reg mix $25 Walmart OTC vial Novolog 70/30 aspart mix $240 10ml, $ ml $5 OTC vial, $5 vial, $5 vial, vial, vial, vial, vial, vial vial, vial vial, vial Glucometers United Healthcare Accu-Chek Aviva Plus, Accu-Chek Compact Plus free meter* Accu-check compact plus foote Bayer Breeze 2/ Bayer Contour free meter* Freestyle Lite/ Freestyle Freedom Lite free meter* Freestyle, Freestyle Lite Freestyle Freedom Lite (kit & strips) foote Onetouch (Ultra2, Ultramini, or Verio) free meter* may One Touch Verio Sure, Fast Take, Verio, Ultra 2 strips/day Ultra 2, (no insulin) 6 Ultra Mini, strips/day Verio (insulin) - glucometer. Website and customer service both say accu-chek (AvivaPlus, Compact, Nano 100 stp/30d) and freestyle (Lite, Freedom Lite), but pharmacists tell us onetouch glucometer/lancets (verio, ultra2, ultramini) although says. *** : Accu-Chek or One Touch glucometers- call

Objectives. How Medicine Works to Control Blood Sugar Levels. What Happens When We Eat? What is diabetes? High Blood Glucose (Hyperglycemia)

Objectives. How Medicine Works to Control Blood Sugar Levels. What Happens When We Eat? What is diabetes? High Blood Glucose (Hyperglycemia) How Medicine Works to Control Blood Sugar Levels Stacie Petersen, RN, CDE Objectives Define Diabetes List how medications work (ominous octet) Identify side effects of medications for diabetes What is

More information

What the Pill Looks Like. How it Works. Slows carbohydrate absorption. Reduces amount of sugar made by the liver. Increases release of insulin

What the Pill Looks Like. How it Works. Slows carbohydrate absorption. Reduces amount of sugar made by the liver. Increases release of insulin Diabetes s Oral s - Pills These are some of the pills that are currently available in Canada to treat diabetes. Each medication has benefits and side effects you should be aware of. Your diabetes team

More information

1/15/2018. Disclosures. Current Diabetes Medications. Objectives NON-INSULIN AGENTS. Diabetes Med Classes. Mealtime

1/15/2018. Disclosures. Current Diabetes Medications. Objectives NON-INSULIN AGENTS. Diabetes Med Classes. Mealtime Disclosures Current Diabetes Medications None Claire Baker, M.D. Diabetes & Endocrine Associates January 24, 2018 Objectives Identify categories of diabetes medications Understand the pharmacology of diabetes

More information

Diabetes Medication Updates Erica Bukovich, PharmD, BC-ADM, CDE September 20, 2018

Diabetes Medication Updates Erica Bukovich, PharmD, BC-ADM, CDE September 20, 2018 Diabetes Medication Updates Erica Bukovich, PharmD, BC-ADM, CDE September 20, 2018 Learning Objectives Identify medication classes available for treatment of individuals with diabetes. Demonstrate understanding

More information

Diabetes Treatment Guidelines

Diabetes Treatment Guidelines Diabetes Treatment Guidelines For more comprehensive information about current approaches to the diagnosis and treatment of diabetes, visit the American Diabetes Association Standards of Medical Care 2018

More information

Clinical Pharmacotherapeutic Applications of the American Diabetes Association Standards of Care 2018

Clinical Pharmacotherapeutic Applications of the American Diabetes Association Standards of Care 2018 Clinical Pharmacotherapeutic Applications of the American Diabetes Association Standards of Care 2018 RACHEL NAIDA, PHARMD, CDE CLINICAL ASSOCIATE PROFESSOR UNIVERSITY OF NEW ENGLAND COLLEGE OF PHARMACY

More information

Collaborative Practice Agreement

Collaborative Practice Agreement Collaborative Practice Agreement [community pharmacy name] [address] [phone number] [physician practice] [address] [phone number] Effective: [date] Expiration: [date] 1 Table of Contents 1.0 Introduction...4

More information

Pharmacology Updates. Quang T Nguyen, FACP, FACE, FTOS 11/18/17

Pharmacology Updates. Quang T Nguyen, FACP, FACE, FTOS 11/18/17 Pharmacology Updates Quang T Nguyen, FACP, FACE, FTOS 11/18/17 14 Classes of Drugs Available for the Treatment of Type 2 DM in the USA ### Class A1c Reduction Hypoglycemia Weight Change Dosing (times/day)

More information

TABLE 1A: Formulary Coverage of Insulin Therapies & Indications for Use in Various Populations

TABLE 1A: Formulary Coverage of Insulin Therapies & Indications for Use in Various Populations 177 TABLE 1A: Formulary Coverage of Insulin Therapies & Indications for Use in Various Populations TABLE 1A : Formulary Coverage of Insulin Therapies & Indications for Use in Various Populations Formulary

More information

TABLE 1A : Formulary Coverage of Insulin Therapies & Indications for Use in Various Populations

TABLE 1A : Formulary Coverage of Insulin Therapies & Indications for Use in Various Populations 177 TABLE 1A : Formulary Coverage of Insulin Therapies & Indications for Use in Various Populations Formulary Coverage Indication for use with: INSULIN THERAPY NS NB NL PE ADULTS PEDIATRICS PREGNANCY BOLUS

More information

Images have been removed from the PowerPoint slides in this handout due to copyright restrictions. Insulins. Rapid Short Intermediate Long Mix

Images have been removed from the PowerPoint slides in this handout due to copyright restrictions. Insulins. Rapid Short Intermediate Long Mix Diabetes Medications Diabetes Medications Type 1 Insulin is needed Type 2 Oral Diabetes Medications Or Oral Diabetes Medications plus Insulin Or Insulin Alone Diabetes Medications Secretagogues Glipizide

More information

RPCC Pharmacy Forum. The Type 2 Diabetes Issue. Type 2 Diabetes: The Basics

RPCC Pharmacy Forum. The Type 2 Diabetes Issue. Type 2 Diabetes: The Basics Nov/Dec 2015 Issue 11 RPCC Pharmacy Forum Special Interest Articles: Diabetes Medication Chart Insulin Chart Afreeza Did you know? Exanatide, marketed as Byetta, is the synthetic form of exendin-4, which

More information

Diabetes Mellitus II CPG

Diabetes Mellitus II CPG 1 Diabetes Mellitus II CPG Candidates for Screening Integrated Complex Care Patients: Check Yearly Prediabetes: Check Yearly No Diabetes Mellitus (DM) Risk Factors: Check at Age 45, Repeat Every 3 Years

More information

STEP THERAPY CRITERIA

STEP THERAPY CRITERIA CATEGORY DRUG CLASS BRAND NAME (generic) STEP THERAPY CRITERIA AMYLIN ANALOG: SYMLIN/SYMLINPEN (pramlintide acetate) ANTIDIABETIC AGENTS GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST (GLP-1): ADLYXIN (lixisenatide)

More information

3. Cardiovascular Disease?

3. Cardiovascular Disease? Swiss recommendations 2016 Swiss Society of Endocrinology and Diabetology 1. Deficiency? Basal Premixed- Basal + GLP-1 RA (Xultophy ) or Basal Bolus 2. egfr < 30 ml/min? 3. Cardiovascular Disease? 4. Heart

More information

Clinical Cases in Diabetes Management. Joseph Cook D.O.

Clinical Cases in Diabetes Management. Joseph Cook D.O. Clinical Cases in Diabetes Management Joseph Cook D.O. Objectives State the prevalence of Diabetes Mellitus in Ohio State the percentage of diabetic patients in the U.S. treated by Primary Care Physicians

More information

Pharmacologic Agents for Treatment of Type 2 Diabetes

Pharmacologic Agents for Treatment of Type 2 Diabetes Pharmacologic Agents for Treatment of Type 2 Diabetes SCAN Drugs Medication Biguanides 1 1 er uncoated tabs 500 mg & 750 mg Sulfonylureas 1 1 500 850 mg QD - TID 500 2000 mg glimepiride 1 1 1 8 mg glipizide

More information

Physician Drug Reference Chart for Diabetes Antidiabetic Medications

Physician Drug Reference Chart for Diabetes Antidiabetic Medications Drug Class Compound Brand Name Mechanism of Action Advantages Disadvantages Alpha-glucosidase inhibitors Medium Cost by Bayer Healthcare, Pfizer, Takeda Research Acarbose Miglitol Voglibose Precose Glyset

More information

Managing Complex Diabetes Cases: Medication Update. Celia Levesque MSN, RN, CNS-BC, CDE, BC-ADM

Managing Complex Diabetes Cases: Medication Update. Celia Levesque MSN, RN, CNS-BC, CDE, BC-ADM Managing Complex Diabetes Cases: Medication Update Celia Levesque MSN, RN, CNS-BC, CDE, BC-ADM clevesqu@mdanderson.org Objectives Describe how each diabetes medication class is used to treat diabetes Differentiate

More information

What s New in Type 2 Diabetes? 2018 Diabetes Updates

What s New in Type 2 Diabetes? 2018 Diabetes Updates What s New in Type 2 Diabetes? 2018 Diabetes Updates Gretchen Ray, PharmD, PhC, BCACP, CDE Associate Professor, UNM College of Pharmacy January 28, 2018 gray@salud.unm.edu OBJECTIVES Describe the most

More information

Type 2 Diabetes: Where Do We Start with Treatment? DIABETES EDUCATION. Diabetes Mellitus: Complications and Co-Morbid Conditions

Type 2 Diabetes: Where Do We Start with Treatment? DIABETES EDUCATION. Diabetes Mellitus: Complications and Co-Morbid Conditions Diabetes Mellitus: Complications and Co-Morbid Conditions ADA Guidelines for Glycemic Control: 2016 Retinopathy Between 2005-2008, 28.5% of patients with diabetes 40 years and older diagnosed with diabetic

More information

Management of Type 2 Diabetes Mellitus. Heather Corn, MD, MS Endocrinology, Diabetes, and Metabolism

Management of Type 2 Diabetes Mellitus. Heather Corn, MD, MS Endocrinology, Diabetes, and Metabolism Management of Type 2 Diabetes Mellitus Heather Corn, MD, MS Endocrinology, Diabetes, and Metabolism Disclosures Working for Intermountain Healthcare Some of the views represented are the opinion of ABIM-certified

More information

Jonathan Stoehr, MD PhD Endocrinology, Diabetes, Metabolism and Nutrition Virginia Mason Medical Center Seattle, WA 2012 Virginia Mason Medical

Jonathan Stoehr, MD PhD Endocrinology, Diabetes, Metabolism and Nutrition Virginia Mason Medical Center Seattle, WA 2012 Virginia Mason Medical Jonathan Stoehr, MD PhD Endocrinology, Diabetes, Metabolism and Nutrition Virginia Mason Medical Center Seattle, WA There is no conflict of interest that could be perceived as prejudicing the impartiality

More information

Objectives. Recognize all available medical treatment options for diabetes. Individualize treatment and glycemic target based on patient factors

Objectives. Recognize all available medical treatment options for diabetes. Individualize treatment and glycemic target based on patient factors No disclosure Objectives Recognize all available medical treatment options for diabetes Individualize treatment and glycemic target based on patient factors Should be able to switch to more affordable

More information

Very Practical Tips for Managing Type 2 Diabetes

Very Practical Tips for Managing Type 2 Diabetes Very Practical Tips for Managing Type 2 Diabetes Jean-François Yale, MD, FRCPC McGill University Health Centre, Montreal, Canada Jean-francois.yale@mcgill.ca www.dryale.ca OBJECTIVES DISCLOSURES The participant

More information

What s New in Type 2 Diabetes? 2018 Diabetes Updates

What s New in Type 2 Diabetes? 2018 Diabetes Updates What s New in Type 2 Diabetes? 2018 Diabetes Updates Jessica Conklin, PharmD, PhC, BCACP, CDE, AAHIP Associate Professor, UNM College of Phar macy jeconklin@salud.unm.edu Luis Gonzales, PharmD, PhC UNM

More information

Diabetes Medications: Oral Anti-Hyperglycemic Medications

Diabetes Medications: Oral Anti-Hyperglycemic Medications Diabetes Medications: Oral Anti-Hyperglycemic Medications Medication Types 1. Biguanides 2. Sulfonylureas 3. Thiazolidinediones (TZDs) 4. Alpha-Glucosidase Inhibitors 5. D-Phenylalanine Meglitinides 6.

More information

2018 Diabetes Summit Managing Diabetes: An Art and a Science

2018 Diabetes Summit Managing Diabetes: An Art and a Science 2018 Diabetes Summit Managing Diabetes: An Art and a Science Natasha Petry, PharmD, BCACP NDSU College of Health Professions, School of Pharmacy, Department of Pharmacy Practice Patient-Centered Medical

More information

Table 1. Antihyperglycemic agents for use in type 2 diabetes

Table 1. Antihyperglycemic agents for use in type 2 diabetes Table 1. Antihyperglycemic agents for use in type 2 diabetes DRUG IN ALPHA-GLUCOSIDASE INHIBITOR: inhibits pancreatic alpha-amyle and intestinal alpha-glucoside Acarbose (Glucobay) 0.6% Negligible Not

More information

Update on Therapies for Type 2 Diabetes: Angela D. Mazza, DO July 31, 2015

Update on Therapies for Type 2 Diabetes: Angela D. Mazza, DO July 31, 2015 Update on Therapies for Type 2 Diabetes: 2015 Angela D. Mazza, DO July 31, 2015 Objectives To present the newer available therapies for the management of T2D To discuss the advantages and disadvantages

More information

Drug Therapy in Diabetes HEATHER TINGLE UK COLLEGE OF PHARMACY, PY4

Drug Therapy in Diabetes HEATHER TINGLE UK COLLEGE OF PHARMACY, PY4 Drug Therapy in Diabetes HEATHER TINGLE UK COLLEGE OF PHARMACY, PY4 OVERVIEW Characteristic Type 1 DM (10%) Type 2 DM (90%) Formerly known as Juvenile; Insulin-dependent Adult onset; Non-insulin dependent

More information

Welcome to the PHASE Learning Community! October 31, 2018

Welcome to the PHASE Learning Community! October 31, 2018 Welcome to the PHASE Learning Community! October 31, 2018 Webinar Housekeeping 1. Dial in for audio: 303-248-0285, Access Code: 5617817 2. Lines are muted. You can chat in questions or unmute your line

More information

Non-Insulin Diabetes Medications Summary

Non-Insulin Diabetes Medications Summary Non-Insulin Diabetes Medications Summary Medications marked with an asterisk (*) can cause hypoglycemia INSULIN SECRETAGOGUES Sulfonylureas* GLYBURIDE* (Diabeta) (Micronase) production. Side effects: Potential

More information

INSIGHTS PRACTICE INSULIN, PRIOR AUTHORIZATION, AND UTILIZATION MANAGEMENT DECEMBER 2017 DEVELOPED BY THE AMERICAN PHARMACISTS ASSOCIATION

INSIGHTS PRACTICE INSULIN, PRIOR AUTHORIZATION, AND UTILIZATION MANAGEMENT DECEMBER 2017 DEVELOPED BY THE AMERICAN PHARMACISTS ASSOCIATION PRACTICE DECEMBER 2017 INSIGHTS INSULIN, PRIOR AUTHORIZATION, AND UTILIZATION MANAGEMENT DEVELOPED BY THE AMERICAN PHARMACISTS ASSOCIATION SUPPORTED BY SANOFI Contents Introduction... 1 Diabetes Management

More information

DIABETES. overview of pharmacologic agents used in the management of. Overview 4/3/2014 OBJECTIVES. Injectable Agents

DIABETES. overview of pharmacologic agents used in the management of. Overview 4/3/2014 OBJECTIVES. Injectable Agents overview of pharmacologic agents used in the management of DIABETES Kyle Roberts, Pharm.D. PGY-1 Pharmacy Resident Saint Alphonsus RMC 1. List the different classes of diabetes medications, including the

More information

Improving Patient Outcomes with Individualized Therapy in the Management of Type 2 Diabetes

Improving Patient Outcomes with Individualized Therapy in the Management of Type 2 Diabetes Improving Patient Outcomes with Individualized Therapy in the Management of Type 2 Diabetes Timothy S. Reid, M.D. Mercy Diabetes Center Janesville, WI Duality Statement Dr. Reid is a Speaker and Consultant

More information

6/1/2018. Lou Haenel, IV, DO, FACE, FACOI Endocrinology Roper St Francis Charleston, SC THE OMINOUS OCTET: HOW PATHOPHYSIOLOGY AND THERAPY MERGE

6/1/2018. Lou Haenel, IV, DO, FACE, FACOI Endocrinology Roper St Francis Charleston, SC THE OMINOUS OCTET: HOW PATHOPHYSIOLOGY AND THERAPY MERGE Lou Haenel, IV, DO, FACE, FACOI Endocrinology Roper St Francis Charleston, SC THE OMINOUS OCTET: HOW PATHOPHYSIOLOGY AND THERAPY MERGE 1 2 3 Sulfonylureas Glipizide Glyburide Glimeperide 4 Metformin Gold

More information

Diabetes 2016: Strategies for achieving optimal diabetes control

Diabetes 2016: Strategies for achieving optimal diabetes control PHASE Safety Net Community Benefit Diabetes 2016: Strategies for achieving optimal diabetes control Presented by: Lisa Gilliam, MD, PhD Clinical Leader Diabetes Program Kaiser Permanente Northern California

More information

Deaths Hospitalizations Company. Takeda Pharmaceuticals. Takeda Pharmaceuticals. Takeda Pharmaceuticals. Janssen Pharmaceuticals

Deaths Hospitalizations Company. Takeda Pharmaceuticals. Takeda Pharmaceuticals. Takeda Pharmaceuticals. Janssen Pharmaceuticals Takeaways: Diabetes Drug Investigation From: BSardi@aol.com Sent: Mon, Dec 22, 2014 at 10:51 am To: Cc: gemcap2@reagan.com martie.whittekin@verizon.net, katjames008@gmail.com clip_image002.jpg (64.5 KB)

More information

Antidiabetic Agents CHAPTER BIGUANIDES

Antidiabetic Agents CHAPTER BIGUANIDES ajt/shutterstock, Inc. CHAPTER 2 Antidiabetic Agents Charles Ruchalski, PharmD, BCPS BIGUANIDES For newly diagnosed patients with type 2 diabetes, the biguanide metformin is the drug of choice for initial

More information

Update on Diabetic Medications UMA SUNDARAM, M.D. DIABETES & ENDOCRINE ASSOCIATES APRIL 07, 2018

Update on Diabetic Medications UMA SUNDARAM, M.D. DIABETES & ENDOCRINE ASSOCIATES APRIL 07, 2018 Update on Diabetic Medications UMA SUNDARAM, M.D. DIABETES & ENDOCRINE ASSOCIATES APRIL 07, 2018 Disclosure NONE Objectives To identify different categories of diabetes medications Understand the pharmacology

More information

Clinical Practice Guidelines

Clinical Practice Guidelines Clinical Practice Guidelines Diabetes Objective The purpose is to guide the appropriate diagnosis and management of Diabetes. This guideline is designed to assist the clinician by providing a framework

More information

Diabetes Update 2018: Challenging Transitions. Patricia A. Daly, MD, FACP, FACE Medical Director for Diabetes Valley Health System

Diabetes Update 2018: Challenging Transitions. Patricia A. Daly, MD, FACP, FACE Medical Director for Diabetes Valley Health System Diabetes Update 2018: Challenging Transitions Patricia A. Daly, MD, FACP, FACE Medical Director for Diabetes Valley Health System 1 Patricia A. Daly, MD, FACP, FACE Medical Director for Diabetes Valley

More information

Diabetes Management: A diagnostic perspective

Diabetes Management: A diagnostic perspective Diabetes Management: A diagnostic perspective Images: http://www.engadget.com/2009/09/23/bayer-introduces-countour-usb-glucose-meter/ http://www.medtronicdiabetes.com/treatment-and-products/minimed-530g-diabetes-system-with-enlite

More information

Diabetes Update 2018: Challenging Transitions. Patricia A. Daly, MD, FACP, FACE Medical Director for Diabetes Valley Health System

Diabetes Update 2018: Challenging Transitions. Patricia A. Daly, MD, FACP, FACE Medical Director for Diabetes Valley Health System Diabetes Update 2018: Challenging Transitions Patricia A. Daly, MD, FACP, FACE Medical Director for Diabetes Valley Health System 1 Patricia A. Daly, MD, FACP, FACE Medical Director for Diabetes Valley

More information

Diabetes Update 10/12/2017. Section #1 OBJECTIVE. Lab features to consider:

Diabetes Update 10/12/2017. Section #1 OBJECTIVE. Lab features to consider: Section #1 OBJECTIVE Diabetes Update Fall 2017 Lyle Myers BE ABLE TO DIFFERENTIATE TYPE 1 FROM TYPE 2 DIABETES Clinical features: - age at onset - body weight/bmi - family history - treatment history -

More information

Diabetes Update Bryan Heart Conference September 5, 2015 Shannon Wakeley, MD. Disclosures. Objectives 9/1/2015

Diabetes Update Bryan Heart Conference September 5, 2015 Shannon Wakeley, MD. Disclosures. Objectives 9/1/2015 Diabetes Update Bryan Heart Conference September 5, 2015 Shannon Wakeley, MD Disclosures I speak on behalf of the following companies: Astra Zeneca, Boehringer Ingelheim, Johnson & Johnson, Sanofi and

More information

Fee-for-Service Pharmacy Provider Notice #216 ** March 2016 PDL Changes ** Existing Drug Classes

Fee-for-Service Pharmacy Provider Notice #216 ** March 2016 PDL Changes ** Existing Drug Classes Fee-for-Service Pharmacy Provider Notice #216 ** March 2016 PDL Changes ** December 19, 2016 Please be advised that the Department for Medicaid Services (DMS) is making changes to the Kentucky Medicaid

More information

Newer Therapies for Type 2 Diabetes

Newer Therapies for Type 2 Diabetes Newer Therapies for Type 2 Diabetes Sandra Indacochea Sobel, MD Clinical Assistant Professor of Medicine Clinical Chief of Endocrinology, UPMC Mercy Division of Endocrinology, Diabetes, and Metabolism

More information

What s New in Diabetes Medications. Jena Torpin, PharmD

What s New in Diabetes Medications. Jena Torpin, PharmD What s New in Diabetes Medications Jena Torpin, PharmD 1 Objectives Discuss new medications in the management of diabetes Understand the mechanism of the medications discussed Understand the side effects

More information

New Therapies for Diabetes Management: Hope or Headache?

New Therapies for Diabetes Management: Hope or Headache? New Therapies for Diabetes Management: Hope or Headache? Elizabeth Stephens, MD, FACP PMG- Endocrinology Elizabeth.Stephens@providence.org November 2018 Disclosures None 1 Objectives Discussion of 3 rd

More information

Oral Medication for the Management of Diabetes Mechanism of. Duration of Daily Dosing Action

Oral Medication for the Management of Diabetes Mechanism of. Duration of Daily Dosing Action Glyburide (Micronase, Diabeta, Glynase) Glipizide (Glucotrol) Glipizide XL (Glucotrol XL) Glimepiride (Amaryl) Prandin (Repaglinide) Starlix (Nateglinide) 1.25, 2.5, 5mg tabs, Dosing: 2.5-20 mg 12- (Glynase:

More information

Pharmacology. Kacy Aderhold, MSN, APRN-CNS, CMSRN

Pharmacology. Kacy Aderhold, MSN, APRN-CNS, CMSRN Pharmacology Kacy Aderhold, MSN, APRN-CNS, CMSRN Biguanides Decreases hepatic glucose production and improves insulin sensitivity (increases number of insulin receptors) Common Adverse Reaction: diarrhea

More information

The Management of Diabetes in Primary Care Kelly Krawtz, PharmD, BCPS, BCACP

The Management of Diabetes in Primary Care Kelly Krawtz, PharmD, BCPS, BCACP The Management of Diabetes in Primary Care Kelly Krawtz, PharmD, BCPS, BCACP Objectives Explain the current pharmacologic options for the management of diabetes Describe the latest technologies available

More information

4/9/2018 HOW TO REGULATE DIABETES MEDICATIONS. By Sarah Froemsdorf MSN, RNC, CDE, FNP DISCLOSURES NONE. Diagnosis

4/9/2018 HOW TO REGULATE DIABETES MEDICATIONS. By Sarah Froemsdorf MSN, RNC, CDE, FNP DISCLOSURES NONE. Diagnosis HOW TO REGULATE DIABETES MEDICATIONS By Sarah Froemsdorf MSN, RNC, CDE, FNP DISCLOSURES NONE Diagnosis 1 NORMAL BODY The normal pancreas releases one unit of insulin every hour all day. The normal pancreas

More information

Search strategies key terms

Search strategies key terms Online Resource - Search strategies key terms - Table S1a,b: characteristics RCTs comparing GLP-1 with insulin - Table S2a,b: characteristics observational studies comparing DPP-4i with sulfonylurea -

More information

I. General Considerations

I. General Considerations 1 2 3 I. General Considerations A. Type I ( Juvenile Onset or IDDM) IDDM results from autoimmune destruction of beta cells inability to secrete insulin --> ketone formation --> DKA 4 Diabetic Ketoacidosis

More information

Advanced Practice Education Associates. Endocrine

Advanced Practice Education Associates. Endocrine Advanced Practice Education Associates Endocrine Overview Diabetes Thyroid Disease 162 Copyright 2016 Advanced Practice Education Associates DIABETES MELLITUS What is the BMI cut point for screening adults

More information

Clinical Guidelines. Management of adult patients with diabetes undergoing endoscopic procedures

Clinical Guidelines. Management of adult patients with diabetes undergoing endoscopic procedures Clinical Guidelines Management of adult patients with diabetes undergoing endoscopic s Document Detail Document type Clinical Guideline Management of adult Patients with diabetes Undergoing Document name

More information

Disclosures. Objectives. Bryan Cardiology Conference DM2 & Cardiovascular Outcome Trials 8/28/2017

Disclosures. Objectives. Bryan Cardiology Conference DM2 & Cardiovascular Outcome Trials 8/28/2017 Bryan Cardiology Conference DM2 & Cardiovascular Outcome Trials Shannon Wakeley MD Complete Endocrinology 9/2/2017 Disclosures Speakers Bureau: Astra Zeneca, Sanofi, Abbvie, Boehringer-Ingelheim, Medtronic,

More information

New Therapies for Diabetes

New Therapies for Diabetes Type 2 diabetes is increasingly prevalent New Therapies for Diabetes Lynn Mack, M.D. Associate Professor Diabetes, Endocrinology, & Metabolism The Nebraska Medical Center lmack@unmc.edu No Conflicts of

More information

Glycemic Management of Type 2 Diabetes. Gail Nunlee-Bland, M.D. Professor Medicine & Pediatrics Director, Diabetes Treatment Center Howard University

Glycemic Management of Type 2 Diabetes. Gail Nunlee-Bland, M.D. Professor Medicine & Pediatrics Director, Diabetes Treatment Center Howard University Glycemic Management of Type 2 Diabetes Gail Nunlee-Bland, M.D. Professor Medicine & Pediatrics Director, Diabetes Treatment Center Howard University 1 None Disclosures Learning Objectives Understand the

More information

How to Fight Diabetes and Win. Diabetes. Medications

How to Fight Diabetes and Win. Diabetes. Medications How to Fight Diabetes and Win Diabetes Medications MEDICATIONS FOR DIABETES According to the American Diabetes Association, 85% of adults diagnosed with diabetes take insulin and/or oral medication to

More information

The Death of Sulfonylureas? A Review of New Diabetes Medications

The Death of Sulfonylureas? A Review of New Diabetes Medications The Death of Sulfonylureas? A Review of New Diabetes Medications Kelly Hoenig, Pharm.D., BCPS Cedar Rapids Family Medicine Residency 2/4/17 Objectives Review GLP-1 Agonists, DPP-IV Inhibitors and SGLT-2

More information

Inpatient Glycemic Management:

Inpatient Glycemic Management: Disclosure to Participants Conflict of Interest (COI) and Financial Relationship Disclosures: Dr. Seley attended Advisory Board Meeting: Alliance (Boehringer-Ingelheim/Lilly) Bayer Diabetes Care Sanofi

More information

HYPOGLYCEMIA MANAGEMENT IN DIABETES

HYPOGLYCEMIA MANAGEMENT IN DIABETES Scenes and Seminars on HYPOGLYCEMIA MANAGEMENT IN DIABETES Multidisciplinary Approaches to Improving Safety for Patients With Diabetes FEATURING: Etie Moghissi, MD, FACP, FACE Program Chair Davida F Kruger,

More information

Cardiovascular Impact of Medications for Treating Type 2 Diabetes

Cardiovascular Impact of Medications for Treating Type 2 Diabetes Friday CME Breakfast Lecture Cardiovascular Impact of Medications for Treating Type 2 Diabetes Thomas Blevins, MD Endocrinologist, Private Practice Texas Diabetes and Endocrinology Austin, Texas Educational

More information

Diabetes Basics. Type 1 diabetes The body cannot make insulin Requires insulin injection Is not treated with oral diabetes medicines (pills)

Diabetes Basics. Type 1 diabetes The body cannot make insulin Requires insulin injection Is not treated with oral diabetes medicines (pills) Diabetes Basics What is Diabetes? Diabetes is a disease in which the pancreas is unable to make insulin or the body is unable to use insulin or both. This leads to high blood sugar levels in the blood.

More information

Disclosures. Objectives 11/2/2015. Type 2 Diabetes Mellitus: Medication Update. Diabetes Recommendations. Main Pathophysiological Defects in T2DM

Disclosures. Objectives 11/2/2015. Type 2 Diabetes Mellitus: Medication Update. Diabetes Recommendations. Main Pathophysiological Defects in T2DM Type 2 Diabetes Mellitus: Medication Update Which One Should the NP Use? Iowa Nurse Practitioner Society Dr. Dixie Harms, DNP, ARNP, FNP-C, BC-ADM, FAANP November 2015 Disclosures Speaker s Bureau Novo

More information

Drug Class Review Newer Diabetes Medications and Combinations

Drug Class Review Newer Diabetes Medications and Combinations Drug Class Review Newer Diabetes Medications and Combinations Final Update 2 Report July 2016 The purpose reports is to make available information regarding the comparative clinical effectiveness and harms

More information

Making Sense of New DM Therapies and Technologies

Making Sense of New DM Therapies and Technologies Making Sense of New DM Therapies and Technologies Sandra Indacochea Sobel, MD Clinical Assistant Professor of Medicine Clinical Chief of Endocrinology, UPMC Mercy Division of Endocrinology, Diabetes, and

More information

Prevalence of Diabetes Mellitus Affects 9.3% of the US popularon (29.1 million people) 1 Seventh leading cause of death in the US 1

Prevalence of Diabetes Mellitus Affects 9.3% of the US popularon (29.1 million people) 1 Seventh leading cause of death in the US 1 What is diabetes? DIABETES: Treatment and Management Steven Ferrucci, OD, FAAO Chief, Optometry, Sepulveda VA Professor, SCCO/MBKU DM is a chronic disorder characterized by a lack of insulin or increased

More information

Date of Review: September 2016 Date of Last Review: September 2015

Date of Review: September 2016 Date of Last Review: September 2015 Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

Healthy You: A Guide to Diabetes Self-Care SURVIVAL SKILLS

Healthy You: A Guide to Diabetes Self-Care SURVIVAL SKILLS Healthy You: A Guide to Diabetes Self-Care SURVIVAL SKILLS Table of Contents Introduction 3 Monitoring Your Diabetes 7 Medications 11 Problem Solving 24 Healthy Eating with Diabetes 26 Managing Sick Days

More information

Let s not sugarcoat it! Update on Pharmacologic Management of Type II DM

Let s not sugarcoat it! Update on Pharmacologic Management of Type II DM Let s not sugarcoat it! Update on Pharmacologic Management of Type II DM Gregory Castelli, PharmD, BCPS, BC-ADM Clinical Pharmacist UPMC St. Margaret Objectives By the end of this presentation, participants

More information

Initiating Injectable Therapy in Type 2 Diabetes

Initiating Injectable Therapy in Type 2 Diabetes Initiating Injectable Therapy in Type 2 Diabetes David Doriguzzi, PA C Learning Objectives To understand current Diabetes treatment guidelines To understand how injectable medications fit into current

More information

continuing education for pharmacists

continuing education for pharmacists continuing education for pharmacists 2016 AACE/ACE Guidelines on Type 2 Diabetes Management and New Glycemic Control Agents Amanda R. Kriesen, R.Ph., PharmD, and Erin Bastick, R.Ph., PharmD Volume XXXV,

More information

PRIOR AUTHORIZATION BYPASS Tanzeum (albiglutide) Bypass the Prior Authorization by Modifying the following Prescription Forms to the Patient's Needs

PRIOR AUTHORIZATION BYPASS Tanzeum (albiglutide) Bypass the Prior Authorization by Modifying the following Prescription Forms to the Patient's Needs Please ote: Medical ecessity Prior Authorization may be overrided for both formulary coverage and benefit design restrictions. They are issued at the full discretion of the benefit manager. PRIOR AUTHORIZATIO

More information

Report Writing Specifications

Report Writing Specifications Report Writing Specifications Adverse Drug Events Primary Measures Anticoagulants, Opioids and Hypoglycemic Agents Washington State Hospital Association 2017 Contents Acknowledgements... 2 Terms Used in

More information

DPP4 INHIBITORS. Details. Step Therapy Criteria Health Alliance Plan 2019 Date Effective: 04/01/2019

DPP4 INHIBITORS. Details. Step Therapy Criteria Health Alliance Plan 2019 Date Effective: 04/01/2019 DPP4 INHIBITORS Janumet 50 mg-1,000 mg tablet Januvia 50 mg tablet Janumet 50 mg-500 mg tablet Onglyza 2.5 mg tablet Januvia 100 mg tablet Onglyza 5 mg tablet Januvia 25 mg tablet Tradjenta 5 mg tablet

More information

PRIOR AUTHORIZATION BYPASS Bydureon (long acting exenatide)

PRIOR AUTHORIZATION BYPASS Bydureon (long acting exenatide) Please ote: Medical ecessity Prior Authorization may be overrided for both formulary coverage and benefit design restrictions. They are issued at the full discretion of the benefit manager. PRIOR AUTHORIZATIO

More information

Glucagon-Like Peptide (GLP-1) Receptor Agonists Clinical Edit Criteria

Glucagon-Like Peptide (GLP-1) Receptor Agonists Clinical Edit Criteria Glucagon-Like Peptide (GLP-1) Receptor Agonists Clinical Edit Criteria Drug/Drug Class: Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists Superior HealthPlan follows the guidance of the Texas Vendor Drug

More information

Staying Healthy With Diabetes

Staying Healthy With Diabetes Staying Healthy With Diabetes For: We care. We will listen. We can help. 1 Table of Contents Table of Contents... 2 About Diabetes... 3 Blood Glucose Testing at Home... 4 High and Low Blood Glucose (Sugar)

More information

DPP4 INHIBITORS. Products Affected Step 2: Janumet 50 mg-1,000 mg tablet Janumet 50 mg-500 mg tablet Januvia 100 mg tablet Januvia 25 mg tablet

DPP4 INHIBITORS. Products Affected Step 2: Janumet 50 mg-1,000 mg tablet Janumet 50 mg-500 mg tablet Januvia 100 mg tablet Januvia 25 mg tablet DPP4 INHIBITORS Janumet 50 mg-1,000 mg tablet Janumet 50 mg-500 mg tablet Januvia 100 mg tablet Januvia 25 mg tablet Januvia 50 mg tablet Onglyza 2.5 mg tablet Onglyza 5 mg tablet Tradjenta 5 mg tablet

More information

Limitation of use: GLP-1 Analogs are not recommended for use as first-line therapy in patients inadequately controlled on diet and exercise.

Limitation of use: GLP-1 Analogs are not recommended for use as first-line therapy in patients inadequately controlled on diet and exercise. Clinical Policy: GLP-1 Receptor Agonists Reference Number: AZ.CP.PHAR.42 Effective Date: 11.16.16 Last Review Date: 09.12.18 Line of Business: Arizona Medicaid Revision Log See Important Reminder at the

More information

Oregon Health Plan prescription benefit updates

Oregon Health Plan prescription benefit updates Oregon Health Plan prescription benefit updates EOCCO s prescription program is a pharmacy benefit that offers members a choice of safe and effective medication treatments. The program also helps you save

More information

!"#$%&%'(!)*+'(,(&)%-!'(.#!%('"./0%(( /1#).!(&2()!(((

!#$%&%'(!)*+'(,(&)%-!'(.#!%('./0%(( /1#).!(&2()!((( !"#%&%'(!)*+'(,(&)%-!'(.#!%('"./0%(( /1#).!(&2()!((( 26%5&"7%'( At the end of this presentation, participants should be able to: Evaluate the emerging role of GLP-1 Agonists for weight loss Understand

More information

Victoza (Liraglutide) Solution for Injection

Victoza (Liraglutide) Solution for Injection Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Clinical Edit Information Included in this Document Drugs requiring prior authorization: the list of drugs requiring prior authorization

More information

2/17/2016. Objectives. Define. Hey Sugar! DMII Management in Hospice Care

2/17/2016. Objectives. Define. Hey Sugar! DMII Management in Hospice Care Hey Sugar! DMII Management in Hospice Care Michelle Huber, R.Ph., PharmD.,CGP Objectives Review treatment for hyperglycemia discussing how these medications work, hypoglycemia risk, special considerations.

More information

New Medications and Prescribing Methods for Diabetic Patients

New Medications and Prescribing Methods for Diabetic Patients New Medications and Prescribing Methods for Diabetic Patients Jeffrey Stroup, PharmD, BCPS, FCCP Professor of Medicine Oklahoma State University Center for Health Sciences Department of Internal Medicine

More information

Formulary Medical Necessity Program

Formulary Medical Necessity Program BENEFIT APPLICATION Formulary Medical Necessity Program DRUG POLICY Benefit determinations are based on the applicable contract language in effect at the time the services were rendered. Exclusions, limitations

More information

Antihyperglycemic Agents in Diabetes. Jamie Messenger, PharmD, CPP Department of Family Medicine East Carolina University August 18, 2014

Antihyperglycemic Agents in Diabetes. Jamie Messenger, PharmD, CPP Department of Family Medicine East Carolina University August 18, 2014 Antihyperglycemic Agents in Diabetes Jamie Messenger, PharmD, CPP Department of Family Medicine East Carolina University August 18, 2014 Objectives Review 2014 ADA Standards of Medical Care in DM as they

More information

Glucagon-like peptide-1 (GLP-1) Agonists Drug Class Prior Authorization Protocol

Glucagon-like peptide-1 (GLP-1) Agonists Drug Class Prior Authorization Protocol Glucagon-like peptide-1 (GLP-1) Agonists Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed

More information

Halting the Rise, Newest Non- Insulin Options for Lowering A1c

Halting the Rise, Newest Non- Insulin Options for Lowering A1c Halting the Rise, Newest Non- Insulin Options for Lowering A1c Alecia Rottinghaus, PharmD PGY-1 Pharmacy Resident Iowa City Veterans Affairs Health Care System January 29 th, 2019 Disclosures Alecia Rottinghaus

More information

Halting the Rise, Newest Non- Insulin Options for Lowering A1c

Halting the Rise, Newest Non- Insulin Options for Lowering A1c Halting the Rise, Newest Non- Insulin Options for Lowering A1c Alecia Rottinghaus, PharmD PGY-1 Pharmacy Resident Iowa City Veterans Affairs Health Care System January 29 th, 2019 Disclosures Alecia Rottinghaus

More information

QUESTION #2 QUESTION #4

QUESTION #2 QUESTION #4 DIABETES TREATMENT: AN UPDATE (2018) PHARMACIST AND PHARMACY TECHNICIAN OBJECTIVES Aesha Drozdowski, PharmD, BCPS, BCACP Assistant Professor of Pharmacy Practice Roseman University of Health Sciences College

More information

Remote attendees, please mute your phones as a courtesy thank you!

Remote attendees, please mute your phones as a courtesy thank you! Welcome! Remote attendees, please mute your phones as a courtesy thank you! Diabetes: The Ins and Outs of Insulin CareOregon Pharmacy Today s Agenda Introduction 8:00-8:15am RN perspective 8:15 8:45am

More information

Management of Type 2 Diabetes Mellitus

Management of Type 2 Diabetes Mellitus Quality Department Guidelines for Clinical Care Ambulatory Diabetes Mellitus Guideline Team Team Leaders Connie J Standiford, MD General Internal Medicine Sandeep Vijan, MD General Internal Medicine Team

More information